ClinicalTrials.gg
Status unknownNCT04291248Updated Mar 2, 2020

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

A Phase 2 interventional study of AK105 and Anlotinib in MSI-H or dMMR Advanced Solid Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the efficacy and safety of Anlotinib combined with AK105 injection or AK105 monotherapy in subjects with MSI-H or dMMR advanced solid tumors. In this study, 138 subjects will be enrolled, and those who met the admission criteria will divide into cohort 1 (anlotinib combined with AK105) and cohort 2 (AK105 ). The first phase of this study is a randomized, open-label, parallel-controlled, multicenter design, in which 30 subjects are randomly enrolled in two cohorts. The second phase is to continue enrollment of cohort 1 or cohort 2 when which cohort has the better clinical benefit than the other one.

02

Conditions studied

  • MSI-H or dMMR Advanced Solid Tumors
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Histopathologically confirmed MSI-H or dMMR advanced malignant solid tumors. 2. Has provided previously achieved tumor tissue samples or fresh samples. 3. 18 years and older; (ECOG) performance status score of 0 or 1; ≥ 3 months.

      1. At least one . 5. The main organs function are normally. 6.Male or female subjects should agree to use an adequate method of starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.

      7.Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

  • 1.Has used against , PD-L1 and other related immunotherapeutic drugs. 2. Has received chemotherapy, radiotherapy or other treatments within 4 weeks prior to the first dose.

    1. Has with symptoms or symptoms control for less than 2 months.
    1. Has diagnosed and/or treated additional within 3 years prior to the first dose.
    1. Has multiple factors affecting oral medication. 6.Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
    1. Has unrelieved spinal cord compression. 8. Imaging shows that tumors invade large blood vessels. 9. Has hemoptysis within 1 month prior to the first dose and maximum daily hemoptysis ≥2.5 mL.
    1. Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.
    1. Has received surgery, or unhealed wounds within 4 weeks before the first dose.
    1. Has artery/venous thrombosis prior to the first dose within 6 months. 13. Has drug abuse history that unable to abstain from or mental disorders. 14. Has any serious and / or uncontrolled disease. 15. Has received vaccination or attenuated vaccine within 4 weeks prior to the first dose.
    1. to recombinant humanized anti-PD-1 monoclonal or its components.
    1. Has active diseases requiring systemic treatment occurred within 2 years before the first administration.

    18. therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first dose.

    1. Has a history of active TB. 20. Has participated in other anticancer drug clinical trials within 4 weeks. 20. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Anlotinib+AK105 injection

    AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: AK105 · Drug: Anlotinib

  • Experimental
    AK105 injection

    AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.

    Drug: AK105

Interventions

  • DrugAK105

    AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

  • A multi-target receptor tyrosine kinase inhibitor.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) assessed by Independent Review Committee (IRC)

    Percentage of subjects achieving complete response (CR) and partial response (PR) based on IRC.

    Time frame: up to 96 weeks

Secondary outcomes

  1. Overall response rate (ORR) assessed by investigator

    Percentage of subjects achieving complete response (CR) and partial response (PR) based on investigator.

    Time frame: up to 96 weeks

  2. Disease control rate(DCR)

    Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  3. Duration of Response (DOR)

    DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

    Time frame: up to 96 weeks

  4. Progression-free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 96 weeks

  5. Overall survival (OS)

    OS defined as the time from the first dose to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 96 weeks

07

Study locations

9 sites
  • Beijing Hospital
    Beijing, Beijing 100010, China
    • Yunbo Zhao, Doctor · Contactzhaoyb1206@163.com · 010-85136715
    • Yunbo Zhao, Doctor · Principal investigator
  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100021, China
    • Aiping Zhou, Doctor · Contactzhouap1825@126.com · 010-87788800
    • Aiping Zhou, Doctor · Principal investigator
  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
    • Jianfeng Zhou, Doctor · Contact13910113193@qq.com · 010-69158750
    • Jianfeng Zhou, Doctor · Principal investigator
  • Peking University International Hospital
    Beijing, Beijing 102206, China
  • The Third Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150030, China
    • Yanqiao Zhang, Doctor · Contactyanqiaozhang@126.com · 0451-86298278
    • Yanqiao Zhang, Doctor · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210000, China
    • Jifeng Feng, Doctor · Contactfjf@vip.sina.com · 025-83283415
    • Jifeng Feng, Doctor · Principal investigator
  • The Second Affiliated Hospital of The PLA Air Force Medical University
    Xi'an, Shanxi 710000, China
    • Haichuan Su, Doctor · Contactsuhc@fmmu.edu.cn · 029-84777455
    • Haichuan Su, Doctor · Principal investigator
  • Shanxi Cancer Hospital
    Xi'an, Shanxi 710061, China
    • Zijun Liao, Doctor · Contactliaozijun66@sina.com · 029-85276142
    • Zijun Liao, Doctor · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
    • Ting Deng, Doctor · Contactxymcdengting@126.com · 022-23340123
    • Ting Deng, Doctor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2020; primary completion for Dec 2022, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2020
First posted
Mar 2, 2020
StartEst.
Mar 2020
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04291248
Responsible party
Sponsor
First posted
Mar 2, 2020
Start date
Mar 2020 (estimated)
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Mar 2, 2020

Study contacts

Aiping Zhou, Doctor
Contact
zhouap1825@126.com
010-87788800

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penpulimab

Start the discussion